Trials / Completed
CompletedNCT04925687
Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
Phase 1 Study of the Feasibility and Safety of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Eyes With Vision Loss From Retinitis Pigmentosa
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- University of California, Davis · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this Phase 1 open-labeled prospective study, one eye of each participant with vision loss from retinitis pigmentosa will be administered intravitreal injection of autologous CD34+ stem cells harvested from bone marrow. Each participant will be examined serially for 6 months after study injection to determine safety and feasibility of this intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Intravitreal autologous CD34+ cells | Autologous CD34+ cells harvested from bone marrow injected intravitreal |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2023-11-01
- Completion
- 2023-11-01
- First posted
- 2021-06-14
- Last updated
- 2024-09-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04925687. Inclusion in this directory is not an endorsement.